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Adenosine 3’,5-cyclic monophosphate (CAMP) was shown to stimulate ins&in secretion from electrically 
permeabilised islets of Langerhans incubated in Ca2+/EGTA buffers. CAMP-induced insulin secretion oc- 
curred in the presence of either sub-stimulatory (50 nM) or stimulatory (> 100 nM) concentrations of Ca2+. 
Similar effects on secretion were obtained in response to I-bromo-CAMP (8-Br-CAMP) or the phosphodi- 
esterase inhibitor, 3-isobutyl-l-methylxanthine. Forskolin (0.2-20 PM) increased adenylate cyclase activity 
and enhanced insulin secretion from the ~~eabili~ islets. These results uggest that, in electrically per- 
meabilised islets, CAMP-indu~d insulin secretion isnot dependent on changes incytosohc Ca2+. 
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1. INTRODUCTION 
There is considerable evidence that the in- 
tracellular concentration of CAMP is involved in 
the regulation of insulin secretion from pancreatic 
B-cells [I ,2]. B-cells possess plasma membraue- 
associated adenylate cyclase [3-51 and CAMP- 
dependent protein kinases [6,7], through which it 
is assumed CAMP exerts its intracellular actions. 
Numerous studies have shown that insulin release 
is enhanced in the presence of analogues of CAMP, 
or by increasing intracellular CAMP using agents 
which activate adenylate cyclase or inhibit 
phosphodiesterases ([1,2,8] for references). Several 
hormones and neurotransmitters which affect in- 
sulin secretion are thought to act by receptor- 
mediated alteration of adenylate cyclase activity 
[3,5], and glucose or other metabolic secretagogues 
can elevate intracellular CAMP concentrations 
[2,9], perhaps as a response to increases in 
cytosolic Ga” [2,8,9]. 
We have now studied the effects of changes in 
CAMP concentration on insulin secretion from 
islets of Langerhans which have been permeabilis- 
ed by exposure to a high-intensity electrical field 
[ 101, These electrically permeabilised islets respond 
to increases in Ga2’ concentration over the range 
1O-7-1O-5 M with dose-related increases in insulin 
secretion [I 11. Since low-M, solutes can be in- 
troduced directly into the cytosolic compartment, 
and the intracellular Ca” can be clamped at pre- 
determined concentrations, permeabilised islets of- 
fer a useful model in which to study the relation- 
ships between Ca2+ and other intracellular 
mediators of insulin secretion. 
2. MATERIALS AND METHODS 
Islets of Langerhans were isolated from rat pan- 
creas by collagenase digestion HZ] and incubated 
for 60 min at 37Y.Z in a bicarbonate-buffered 
physiological salt solution [13] containing 2 mM 
glucose, 2 mM GaCl2 and 0.5 mg/ml bovine serum 
albumen (BSA, fraction V, Sigma}. Isolated islets 
were permeabilised by exposure to a high-intensity 
electric field, as described [l I]. Briefly, the islets 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/86/%3.50 0 1986 Federation of European Biochemical Societies 205 
Volume 205, number 2 FEBS LETTERS September 1986 
were thoroughly washed in a Ca’+/EGTA buffer 
(permeation buffer) containing 140 mM K- 
glutamate, 15 mM Hepes, 7 mM MgS04, 5 mM 
adenosine 5 ’ -triphosphate (ATP), 0.5 mg/ml 
BSA, l-5 mM EGTA, pH 6.6, with CaCl2 added 
to produce a Ca2+ concentration of 50 nM, and 
permeabilised by 5 exposures to an electric field of 
3.4 kV/cm. Groups of 10 permeabilised islets were 
incubated at 37°C for 30 min in 1.0 ml of permea- 
tion buffer of various Ca2+ concentrations con- 
taining the test substances of interest. 
3-Isobutyl-1-methylxanthine (IBMX, Sigma) was 
dissolved in dimethyl sulphoxide; forskolin 
(Sigma) was dissolved in 95% ethanol. Controls 
received the appropriate concentration of vehicle 
alone. Insulin secretion by the permeabilised islets 
was measured by radioimmunoassay [ 141. 
Adenylate cyclase activity in homogenates of 
permeabilised islets was assessed by measuring the 
formation of cyclic [w~~P]AMP from 
[w~~P]ATP, as described [3]. The cyclic 
[a-32P]AMP was separated on neutral alumina col- 
umns [3], and radioactivity measured by liquid 
scintillation spectroscopy. Differences between 
means were assessed by analysis of variance or Stu- 
dent’s unpaired t-test, as appropriate. 
3. RESULTS 
In the experiments hown in fig. 1, increasing the 
Ca’+ concentration of the incubation buffer from 
50 nM to 10 pM produced a 2.4-fold increase in in- 
sulin secretion by electrically permeabilised islets in 
the absence of CAMP. Addition of CAMP to the 
incubation medium produced dose-related in- 
creases in insulin secretion in the presence of both 
sub-stimulatory (50 nM) or stimulatory 
(> 100 nM) concentrations of Ca2’ (fig.1). 
Although the absolute amount of CAMP- 
stimulated insulin secretion was greater at higher 
concentrations of Ca2+, the magnitude of the 
CAMP stimulation (i.e. 070 increase over control) 
was very similar over a wide range of Ca2+ concen- 
trations. For example, 100/1M CAMP evoked a 
stimulation of 188 + 14,202 + 21 and 211 + 14% 
at 50 nM, 1 PM and 1OpM Ca”, respectively 
(mean f SE, n = 6-8). The metabolically stable 
analogue 8Br-CAMP had similar, but more 
marked, effects on insulin secretion by the 
permeabilised islets. 
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Fig.1. Stimulation of insulin secretion by CAMP in 
electrically permeabilised islets. The figure shows insulin 
secretion by permeabilised islets incubated in a buffer 
containing various concentrations of Ca2’ and CAMP. 
In the absence of CAMP (0) increasing concentrations 
of Ca2+ stimulate secretion. The presence of 10 /tM (0), 
50 /rM (A) or 100,uM (H) CAMP produced dose-related 
increases in insulin secretion at all concentrations of 
Ca2’. Points show mean f SE, n = 7. 
Fig.2 shows the results of experiments in which 
permeabilised islets were incubated in buffers con- 
taining 10 gM Ca2+ in the presence of 10 and 
1OOpM CAMP or 8-Br-CAMP. In these ex- 
periments, 10pM CAMP had no effect on insulin 
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Fig.2. Effects of CAMP and 8-Br-CAMP on insulin 
secretion by permeabilised islets. CAMP (hatched bars) 
and 8-Br-CAMP (stippled bars) stimulated insulin 
secretion above that induced by 10 PM Ca2+ alone (open 
bar). 8-Br-CAMP produced a maximum effect at a 
concentration of lO/cM @ < 0.05), whereas 1OOpM 
CAMP was required to enhance significantly secretion 
(p < 0.05). Bars show mean + SE, n = 4. 
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release, but 100/1M CAMP produced a significant 
(p < 0.05) stimulation of secretion. 10&l 8-Br- 
CAMP had a greater stimulatory effect than 
100~M CAMP, and this appeared to be a max- 
imum response since no additional stimulation of 
secretion was observed in the presence of 100,uM 
8-Br-CAMP. 
Electrically permeabilised islets possessed a 
functional adenylate cyclase system. Thus, the 
adenylate cyclase activator forskolin (0.2-20 /rM) 
produced dose-related increases in CAMP forma- 
tion in homogenates of permeabilised islets, as 
shown in fig.3 (upper panel). In parallel ex- 
periments, the same concentrations of forskolin 
caused a significant stimulation of insulin secretion 
from electrically permeabilised islets (fig.3, lower 
panel). Insulin secretion by permeabilised islets 
was also stimulated by the phosphodiesterase in- 
hibitor, IBMX. Fig.4 (upper panel) shows the 
significant (p < 0.02) stimulation of insulin secre- 
tion by IBMX (1 mM) at a range of Ca” concen- 
trations. Note that IBMX_ stimulated insulin 
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Fig.3. Effects of forskolin on adenylate cyclase and 
insulin secretion. Upper panel: forskolin (0.2-20 PM) 
produced ose-related increases in CAMP formation by 
homogenates of permeabilised islets, from a basal value 
of 12.6 f 0.6 pmol cAMP/mg protein per 30 min 
(mean f SE, n = 3). Lower panel: forskolin also 
stimulated insulin secretion by permeabilised islets 
incubated in a buffer containing 10 PM Ca*+ (p < 0.05, 
n = 5). 
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Fig.4. IBMX stimulation of insulin secretion by 
permeabilised islets. Upper panel: the addition of 1 mM 
IBMX (hatched bars) to the incubation buffers 
stimulated insulin secretion at both sub-stimulatory 
(50 nM) and stimulatory (10pM) concentrations of 
Ca2+ (mean f SE, n = 5). Lower panel: the effects of 
IBMX in the presence of 50 nM Ca2+ were dose-related. 
Values are expressed as a percentage of secretion in the 
absence of IBMX (mean + SE, n = 6). 
secretion at sub-stimulatory concentrations of 
Ca2+ (50 nM). The effects of IBMX were dose- 
related, with significant stimulation of secretion at 
concentrations of 0.1 mM and above (fig.4, lower 
panel, p < 0.05). 
4. DISCUSSION 
A number of studies have suggested that eleva- 
tions in intracellular CAMP produce an increased 
secretion of insulin from B-cells [ 1,2], but there is 
still some uncertainty as to the importance of 
CAMP in the B-cell secretory response [1,2,8,9]. In 
general, the majority of available experimental 
evidence suggests that CAMP does not initiate in- 
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sulin secretion, but acts to modulate the secretory 
response to initiators of secretion such as glucose 
[2], perhaps by direct actions on Ca2+ fluxes into 
[15] or within [ 161 the B cell or, alternatively, by 
changing the sensitivity of the exocytotic 
mechanisms to Ca2+ [17-191. 
In this study the u;e of electrically permeabilised 
islets ensured that intracellular Ca2+ could be fixed 
at known and pre-determined concentrations. 
Under these conditions, CAMP produced signifi- 
cant increases in insulin secretion by permeabilised 
islets at sub-stimulatory Ca2+ concentrations and 
increased the maximum secretory response to 
Ca2+. In this respe ct the effects of CAMP on in- 
sulin secretion were similar to those previously 
reported for phorbol esters [ 111, which are thought 
to activate protein kinase C [20]. The concentra- 
tions of CAMP effective in promoting secretion 
from the permeabilised islets were somewhat 
higher than those measured in intact islets 
(unstimulated, approx. l-10 pM [6,8,9]) but 
similar responses could be elicited using lower con- 
centrations of metabolically stable analogues of 
CAMP, suggesting that intracellular phosphodi- 
esterase activity was degrading the CAMP, thus 
limiting its effectiveness. Indeed, insulin secretion 
from the permeabilised islets was stimulated by the 
phosphodiesterase inhibitor, IBMX, presumably 
as a response to accumulation of endogenous 
CAMP within the permeabilised cells, although 
IBMX may affect insulin secretion by mechanisms 
other than inhibition of phosphodiesterase activity 
[15]. Increasing CAMP by using the adenylate 
cyclase activator forskolin also stimulated secre- 
tion from electrically permeabilised islets at similar 
concentrations to those which increase secretion 
from intact [ 181 and digitonin-permeabilised islets 
WI. 
It is unlikely that these effects of CAMP on in- 
sulin secretion are a response to CAMP-induced 
fluxes of Ca2+ or other ions [15] across the B-cell 
plasma membrane, since in electrically 
permeabilised islets the intracellular and ex- 
tracellular spaces are in ionic equilibrium. Similar- 
ly, the CAMP-induced secretion is unlikely to be 
caused by mobilisation of Ca2+ from intracellular 
stores [2,16], since changes in intracellular Ca2+ 
should be buffered by the chelator present in the 
medium, although the possibility of transient local 
changes in intracellular Ca2+ cannot be entirely 
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ruled out. These observations do not preclude 
CAMP having effects on insulin secretion by alter- 
ing Ca2+ handling in intact tissue, but they do sug- 
gest that at least part of the secretory response to 
CAMP is not dependent on changes in cytosolic 
Ca’+. Similar conclusions were reached in studies 
using fluorescent indicators to measure cytosolic 
Ca2+ in islets from obese mice [22] and in insulin- 
secreting tumour cells [23], in which the secretory 
responses to dibutyryl CAMP [22], phosphodi- 
esterase inhibitors [22], or forskolin [22,23] were 
not accompanied by measurable increases in 
cytosolic Ca2+. 
The effects of CAMP on insulin secretion by 
permeabilised islets could perhaps be explained by 
a sensitisation of the secretory mechanism to Ca2+, 
thus promoting the exocytosis of insulin at other- 
wise sub-stimulatory concentrations of Ca2+. Such 
an action of CAMP has previously been suggested 
from studies on secretion using intact [ 17-191 or 
digitonin permeabilised [21] islets, and from 
cytosolic Ca2+ measurements in intact tissues 
[22,23]. It is also possible that CAMP may affect 
insulin secretion by altering intracellular concen- 
trations of second messengers other than Ca2+. 
The inhibitory effects of CAMP on serotonin secre- 
tion from platelets are thought to reflect a de- 
creased availability of 1 ,Zdiacylglycerol (DAG) 
[24], presumably by inhibition of phospholipase C 
[24,25]. The possibility that CAMP affects DAG 
production in islets cannot at present be excluded. 
Further studies are required to identify the precise 
mechanisms through which CAMP stimulates in- 
sulin secretion, and to determine the relationships 
between CAMP and other intracellular regulators 
of exocytosis in the B cell. 
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